Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects

NCT01416376 is registered in ClinicalTrials.gov with Sirtris, a GSK Company as lead sponsor.

NCT NCT01416376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01416376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects
Lead sponsor
Sirtris, a GSK Company
Phase
Phase 1
Overall status
Completed
Start date
August 30, 2011
Completion date
December 12, 2011
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis